CLINICAL TRIALS PROFILE FOR LIFILEUCEL
✉ Email this page to a colleague
All Clinical Trials for lifileucel
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03645928 ↗ | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Recruiting | Iovance Biotherapeutics, Inc. | Phase 2 | 2019-05-07 | A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy. |
| NCT05176470 ↗ | Lifileucel and Pembrolizumab for the Treatment of Locally Advanced Stage IIIB-D Melanoma | Not yet recruiting | Iovance Biotherapeutics, Inc. | Phase 1/Phase 2 | 2022-02-01 | This phase I/II trial tests the safety and side effects of lifileucel and pembrolizumab in treating patients with stage IIIB-D melanoma that has spread to nearby tissue or lymph nodes (locally advanced). Biological therapies, such as lifileucel, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lifileucel and pembrolizumab may make the tumor smaller. |
| NCT05176470 ↗ | Lifileucel and Pembrolizumab for the Treatment of Locally Advanced Stage IIIB-D Melanoma | Not yet recruiting | Richard Wu | Phase 1/Phase 2 | 2022-02-01 | This phase I/II trial tests the safety and side effects of lifileucel and pembrolizumab in treating patients with stage IIIB-D melanoma that has spread to nearby tissue or lymph nodes (locally advanced). Biological therapies, such as lifileucel, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lifileucel and pembrolizumab may make the tumor smaller. |
| NCT06151847 ↗ | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | Recruiting | Iovance Biotherapeutics, Inc. | Phase 2 | 2023-12-21 | This phase II trial tests how well lifileucel, with reduce dose fludarabine and cyclophosphamide for lymphodepletion and interleukin-2, work for treating patients with melanoma that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic).Lifileucel is made up of specialized immune cells called lymphocytes or T cells that are taken from a patient's tumor, grown in a manufacturing facility and infused back into the preconditioned patient to attack the tumor. Giving Lifileucel with a reduced dose of fludarabine and cyclophosphamide for lymphodepletion and interleukin -2 is being studied in patients with unresectable or metastatic melanoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for lifileucel
Condition Name
| Condition Name for lifileucel | |
| Intervention | Trials |
| Metastatic Melanoma | 2 |
| Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | 2 |
| Non-small Cell Lung Cancer | 1 |
| Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for lifileucel
Trials by Country
Clinical Trial Progress for lifileucel
Clinical Trial Phase
Clinical Trial Sponsors for lifileucel
Sponsor Name
